

CASE AND RESEARCH LETTER

Assessing the Safety and Efficacy of a New 532-nm and 1064-nm Laser Device With Variable Sequencing and Cryogen Spray Cooling for Rosacea Treatment



Efectividad y seguridad en rosácea de un nuevo dispositivo láser de 532-nm y 1.064-nm con pulsación secuencial variable y enfriamiento por spray criogénico

To the Editor,

Laser and light-based therapies play a significant role in the management of erythematotelangiectatic rosacea (ETR), which frequently exhibits minimal response to medical therapies.¹ Furthermore, research into treatment of rosacea vascular manifestations have often shown an improvement

of the papulopustular component too, probably due to the immunomodulatory effects of light therapies.² This study aims to evaluate the safety and efficacy profile of a novel device that incorporates variable-sequenced, long-pulsed, 532-nm potassium titanyl phosphate (KTP) and 1064-nm neodymium:yttrium–aluminum–garnet (Nd:YAG) lasers with cryogen spray cooling (DermaV, Lutronic®) in patients with ETR.

We conducted a retrospective observational cohort study at the Department of Dermatology of Hospital Ramon y Cajal (Madrid, Spain). Our study included a total of 25 patients with ETR with or without papulopustules that were treated with the above-mentioned device from December 2022 to September 2023. The mean age was 51.7 ± 14.9 years, 72% were women with Fitzpatrick skin type II (72%) or III (28%) (Supplemental Table 1). The median number of sessions was 2 (range 1–5), with a median passes per session of 2 (range 1–6) and a median inter-session interval of 3.7 weeks (IQR, 3–5). Treatment parameters were left at physician's discretion based on previous experience and clinical endpoints during treatment. Table 1 illustrates laser parameters

Table 1 Laser parameters used.

Wavelength	n (%)	No. of sessions (%) ^a	Target	Spot size, mm Median (range)	Pulse duration, ms Median (range)	Fluence, J/cm ² Median (range)	Spray cooling ^b
1064 nm – Nd:YAG							
Single ^α	4 (16.0)	10 (17.2)	Large vessels	9 (8–12)	10 (10–20)	75 (60–120)	15-15-10
532 nm – KTP							
Single ^α	17 (68.0)	33 (56.9)	Large-medium vessels	10 (8–12)	10 (10–10)	10 (5–10)	15-15-10
Sub-millisecond ^β	21 (84.0)	38 (65.5)	Medium-small vessels/background erythema	10 (8–12)	10 (10–10)	10 (5–11)	15-15-10
Sub-microsecond ^δ	19 (76.0)	33 (56.9)	Background erythema	10 (8–12)	10 (6–12)	8 (5–12)	15-15-10

KTP: potassium titanyl phosphate; Nd:YAG: neodymium:yttrium–aluminum–garnet; ^α: continuous pulse; ^β: pulse duration is subdivided into 1.5 ms sub-pulses in succession; ^δ: pulse duration is subdivided into 0.3 ms sub-pulses in succession.

^a The total number of sessions was 58. Percentages in the “Number of Sessions (%)” column refer to the proportion of sessions each wavelength and pulse structure was used.

^b The device allows cooling delivery before and after laser pulse. First value depicts duration of cooling delivery in ms, second value the time prior to pulse delivery, and the third value time of post-cooling in ms (e.g., 15-15-10: 15 ms of cryogen spray, delivered 15 ms prior to laser pulse, with 10 ms post-cooling spray).

<https://doi.org/10.1016/j.ad.2024.01.027>

0001-7310/© 2025 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Table 2 Investigator Global Assessment change after treatment.

Variable	Basal, median (IQR)	Post-treatment ^a , median (IQR)	Mean difference (95%CI)	p-Value
Global IGA	2.3 (2–3)	1 (0.7–1.7)	1.5 (1.2–1.8)	<0.001
IGA for erythema	2 (1.5–2.3)	0.7 (0.3–1)	1.2 (0.9–1.5)	<0.001
IGA for telangiectasia	1.7 (1–2)	0.7 (0.7–1)	0.9 (0.6–1.3)	<0.001
IGA for papulopustules	1 (1–1.7)	0.5 (0–1)	0.7 (0.4–0.9)	<0.001

The final IGA for each patient was the mean of the IGA provided by each of the independent evaluators. With these final IGAs, the baseline and post-treatment IGA of the sample are calculated.

^a 8–12 weeks after the last session; CI: confidence interval; IGA: Investigator Global Assessment; IQR: interquartile range.




Figure 1 Examples of pre- and post-treatment photographs of patients. (A) The patient received 4 sessions. The first one with Nd:YAG for tracing larger telangiectasias (8 mm spot, pulse duration 20 ms with single mode, fluence 60 J/cm²), followed by KTP 10 mm, 10 ms on single mode and 10 J/cm². A second session with similar parameters was conducted, followed by 2 sessions of 2 passes of KTP laser in a single sub-millisecond mode; (B) Patient received 5 sessions of KTP laser in a single pulse mode (10 ms) for medium telangiectasia, with a spot of 12 mm and a fluence ranging 7–8 J/cm², followed by KTP on sub-microsecond pulse mode (10 ms) with a 10 mm spot size and a fluence of 8 J/cm² for background erythema; (C) Results after 5 sessions. Nd:YAG was used for tracing larger telangiectasias (spot 8 mm, pulse duration 10 ms with single mode, fluence ranging 70–120 J/cm²) followed by KTP single mode (10 ms, spot 10–12 mm and fluence of 10 J/cm²) for medium vessels and sub-millisecond and submicrosecond modes (spot size 10–12 mm, fluence 8–10 J/cm² and pulse duration 10 ms) for small vessels and diffuse erythema. A slight hyperpigmentation was observed after session 5 that resolved within the next few weeks.

and [Supplemental Fig. 1](#) depicts pulse modes. Three independent dermatologists evaluated pre- and post-treatment patient photographs and assessed the Investigator's global assessment (IGA) at baseline and 8–12 weeks after treatment, as well as an adapted IGA evaluating erythema, telangiectasias and papulopustules separately. Observers also rated the baseline improvement after treatment on a 5-point ordinal scale: none/worsening (0%); poor (1–25%); mild (25–50%); good (50–75%) and excellent (>75%). Patients reported their degree of satisfaction as very satisfied, satisfied, or dissatisfied, and procedural pain using a visual analog scale from 0 (no pain) up to 10 (extremely painful). Finally, safety and adverse events were collected.

IGA reduced significantly after treatment ([Table 2](#)), being global IGA improvement significantly associated with the number of sessions ($\beta=0.59$; $p=0.003$). There was subjective clinical improvement >50% in 73.3% of cases. Notably, high inter-observe agreement was reported, with weighted kappa coefficients from 0.56 up to 0.74 ($p<0.05$) ([Supplemental Table 2](#)). The median intraoperative pain score was 6 (IQR, 4–7). The most commonly reported adverse event was edema (76% of patients), with a median duration of 3 days (range, 1–10). No purpura was observed. One patient exhibited transient post-inflammatory hyperpigmentation ([Fig. 1C](#)). All patients reported that temporary discomfort was tolerable. Finally, 32% of patients reported being very satisfied, 56% being satisfied and 12% being dissatisfied.

The novel, variable-sequenced, laser device used in the current study showed an adequate safety and effective profile in treating the telangiectasias, redness and papulopustules that characterize rosacea. These results were consistent with those reported by *Bernstein* in a recently published work that included 19 patients with ETR treated with the same device.³ A mean improvement of 39% was observed, being edema the most frequently reported adverse effect. In a study including 23 patients with pigmented and vascular lesions—diagnosis not provided—86.4% were considered responders.⁴ Compared to previous KTP laser devices, the combination of 2 wavelengths and specially the different pulse structures available provides a greater capacity to adapt to the thermal relaxation times of the different vascular structures typical of rosacea, increasing its versatility. Additionally, by increasing the number of pulses delivered, sub-millisecond and sub-microsecond pulse modes increase peak power while maintaining fluence, pulse duration and spot size. This may be particularly important on subsequent treatments, when chromophore decrease forces to increase fluence and, frequently, to reduce the spot size. Maintaining beam diameter ensures an adequate depth of laser penetration and enables faster

treatments. Finally, compared to contact cooling, cryogen spray cooling avoids the risk of compressing blood vessels, thus reducing the chromophore, and enables a more comfortable treatment of the nasal ala. Further research is needed to firmly establish the optimal laser parameters based on the vessel morphology, and compare this device with pulsed-dye laser, which is considered the treatment of choice for vascular lesions of rosacea.⁵ Limitations of the study include its small sample size and retrospective nature.

Conflict of interest

The authors declare that they have no conflict of interest.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.ad.2024.01.027](https://doi.org/10.1016/j.ad.2024.01.027).

References

1. Thiboutot D, Anderson R, Cook-Bolden F, Draelos Z, Gallo RL, Granstein RD, et al. Standard management options for rosacea: the 2019 update by the National Rosacea Society Expert Committee. *J Am Acad Dermatol*. 2020;82:1501–10.
2. Hofmann MA, Lehmann P. Physical modalities for the treatment of rosacea. *JDDG*. 2016;14:38–43.
3. Bernstein EF. A new 532nm, variable-pulse-structure, dual-wavelength, KTP laser incorporating cryogen spray cooling, effectively treats rosacea. *Lasers Surg Med*. 2023, lsm.23700.
4. Wang JV, Bajaj S, Murgia R, Wu SZ, Weiss R, Geronemus RG, et al. Safety and efficacy of a novel, variable-sequenced, long-pulsed, 532-nm and 1064-nm laser with cryogen spray cooling for pigmented and vascular lesions. *Dermatol Surg*. 2023;49:689–92.
5. Husein-ElAhmed H, Steinhoff M. Laser and light-based therapies in the management of rosacea: an updated systematic review. *Lasers Med Sci*. 2021;36:1151–60.

E. Berna-Rico^a, J.J. Lluch-Galcera^{b,*}, B. Pérez-García^a, J. Naharro-Rodríguez^a, C. Azcárraga-Llobet^a, J. Company-Quiroga^a, P. Boixeda^a

^a *Dermatology Department, Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain*

^b *Dermatology Department, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain*

* Corresponding author.

E-mail address: jjlluch@hotmail.com (J.J. Lluch-Galcera).